JNJ-63709178

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameJNJ-63709178

Drug Alias NameCD123 x CD3 DuoBodyCD123-CD3 DuoBody proteinJNJ-63709178CNTO-9958JNJ-9178

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > T cell engagers

Mechanisms of ActionInterleukin-3 receptor subunit alpha inhibitorsCD3 T-cell engagers

TargetsT cell surface glycoprotein CD3Interleukin-3 receptor subunit alpha

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesSpain

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesJohnson & Johnson Innovative Medicine Genmab A/S

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesJanssen Research & Development Llc

Active IndicationsN/A

Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A